Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Contemporary Management of Metastatic Gastrointestinal Stromal Tumors: Systemic and Locoregional Approaches

Contemporary Management of Metastatic Gastrointestinal Stromal Tumors: Systemic and Locoregional... The treatment of metastatic gastrointestinal stromal tumors (GISTs) changed dramatically with the introduction of imatinib into the therapeutic lexicon in 2001. Over the past 15 years, tyrosine kinase inhibitors in the adjuvant and metastatic settings have remained the standard of care for this disease, though alternate classes of agents and new therapeutic targets are being actively explored in clinical trials. Although data are limited, the use of surgical and non-surgical locoregional techniques for the treatment of GIST metastases has increased and given reports of promising and durable responses. Herein we provide an overview of the contemporary therapeutic landscape of metastatic GIST. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Contemporary Management of Metastatic Gastrointestinal Stromal Tumors: Systemic and Locoregional Approaches

Ang, Celina; Maki, Robert
Oncology and Therapy , Volume 4 (1) – Jan 8, 2016
Download PDF
16 pages

Loading next page...
 
/lp/springer-journals/contemporary-management-of-metastatic-gastrointestinal-stromal-tumors-qeiZSTlLRN
Publisher
Springer Journals
Copyright
Copyright © 2016 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-015-0014-7
Publisher site
See Article on Publisher Site

Abstract

The treatment of metastatic gastrointestinal stromal tumors (GISTs) changed dramatically with the introduction of imatinib into the therapeutic lexicon in 2001. Over the past 15 years, tyrosine kinase inhibitors in the adjuvant and metastatic settings have remained the standard of care for this disease, though alternate classes of agents and new therapeutic targets are being actively explored in clinical trials. Although data are limited, the use of surgical and non-surgical locoregional techniques for the treatment of GIST metastases has increased and given reports of promising and durable responses. Herein we provide an overview of the contemporary therapeutic landscape of metastatic GIST.

Journal

Oncology and Therapy – Springer Journals

Published: Jan 8, 2016

References

  • Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
    Hirota, S; Isozaki, K; Moriyama, Y
  • Biology of gastrointestinal stromal tumors
    Corless, CL; Fletcher, JA; Heinrich, MC
  • Gastrointestinal stromal tumors: what do we know now?
    Corless, CL
  • Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations
    Janeway, KA; Kim, SY; Lodish, M
  • Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
    Druker, BJ; Tamura, S; Buchdunger, E
  • Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
    Druker, BJ; Lydon, NB
  • Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
    Joensuu, H; Roberts, PJ; Sarlomo-Rikala, M
  • Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study
    Oosterom, AT; Judson, I; Verweij, J
  • Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
    Demetri, GD; Mehren, M; Blanke, CD
  • Phase III randomized, intergoup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
    Blanke, CD; Rankin, C; Demetri, GD
  • Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomized trial
    Verweij, J; Casali, PG; Zalcberg, J
  • Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT
    Blanke, CD; Demetri, GD; Mehren, M
  • Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
    Heinrich, MC; Owzar, K; Corless, CL
  • Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
    Heinrich, MC; Corless, CL; Demetri, GD
  • KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
    Debiec-Rychter, M; Sciot, R; Cesne, A
  • Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1640 patients
  • Key issues in the clinical management of gastrointestinal stromal tumors: an expert discussion
    Maki, RG; Blay, J-Y; Demetri, GD
  • PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib
    Corless, CL; Schroeder, A; Griffith, D
  • Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib resistant mutants
    Debiec-Rychter, M; Cools, J; Cumez, H
  • Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg
    Zalcberg, JR; Verweij, J; Casali, PG
  • Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial
    Kang, YK; Ryu, MH; Yoo, C
  • Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomized, phase III trial
    Patrikidou, A; Chabaud, S; Ray-Coquard, I
  • Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors
    Demetri, GD; Wang, Y; Wehrle, E
  • We should desist using RECIST, at least in GIST
    Benjamin, RS; Choi, H; Macapinlac, HA
  • Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors
    Desai, J; Shankar, S; Heinrich, MC
  • Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria
    Choi, H; Charnsangavej, C; Faria, SC
  • Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
    Demetri, GD; Oosterom, AT; Garrett, CR
  • Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate
    Prenen, H; Cools, J; Mentens, N
  • Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure
    Demetri, GD; Heinrich, MC; Fletcher, JA
  • Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
    George, S; Blay, JY; Casali, PG
  • Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitnib in imatinib-resistant gastrointestinal stromal tumor
    Heinrich, MC; Maki, RG; Corless, CL
  • Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial
    George, S; Wang, Q; Heinrich, MC
  • Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicenter randomized, placebo-controlled, phase 3 trial
    Demetri, G; Reichardt, P; Kang, Y
  • Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial
    Blay, JY; Shen, L; Kang, YK
  • Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor
    Sawaki, A; Nishida, T; Doi, T
  • Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib
    Montemurro, M; Schoffski, P; Reichardt, P
  • Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib
    Reichardt, P; Blay, JY; Gelderblom, H
  • Nilotinib for treatment of gastrointestinal stromal tumors: out of the equation?
    Kanda, T; Ishikawa, T; Takahashi, T; Nishida, T
  • Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group
    Park, SH; Ryu, MH; Ryoo, BY
  • Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitini (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): final results of a University of Chicago Phase II Consortium trial
    Kindler, HL; Campbell, NP; Wroblewski, K
  • Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: a retrospective analysis
    Montemurro, M; Gelderblom, H; Bitz, U
  • Efficacy of sorafenib in patients with gastrointestinal stromal tumros in the third or fourth-line treatment: a retrospective multicenter experience
    Kefeli, U; Benekli, M; Sevinc, A
  • Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT
    Dubreuil, P; Letard, S; Ciufolini, M
  • Masitinib in imatinib-naïve advanced gastrointestinal stromal tumor (GIST): five-year follow-up of the French Sarcoma Group phase II trial
    Cesne, A; Blay, JY; Nguyen, BB
  • Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial
    Adenis, A; Blay, JY; Bui-Nguyen, B
  • Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate
    Joensuu, H; Braud, F; Coco, P
  • Vatalinib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study
    Joensuu, H; Braud, F; Grignagni, G
  • Long term outcome of dasatinib first-line treatment in gastrointestinal stromal tumors: a multicenter two stage phase II trial SAKK 56/07
    Montemurro, M; Cioffi, A; Domont, J
  • A phase II study of dasatinib for pateients with imatinib-resistant gastrointesitnal stromal tumor (GIST)
    Trent, JC; Wathen, K; Mehren, M
  • Results of SARC 022, a phase II multicenter study of linsitinib in pediatric and adult wild-type (WT) gastrointestinal stromal tumors (GIST)
    Mehren, M; George, S; Heinrich, MC
  • Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
    Kang, YK; Yoo, C; Ryoo, BY
  • Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients
    Garner, AP; Gozgit, JM; Anjum, R
  • A phase 2 study of ponatinib in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after failure of tyrosine kinase inhibitor (TKI) therapy: initial report
    Heinrich, MC; Mehren, M; Demetri, GD
  • A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib
    Ganjoo, KN; Villalobos, VM; Kamaya, A
  • Final results of the multicenter randomized phase II PAZOGIST trial evaluating the efficacy of pazopanib (P) plus best supportive care (BSC) vs BSC alone in resistant unresectable metastatic and/or locally advanced gastrointestinal stromal tumors (GIST)
    Blay, J; Mollimard, M; Cropet, C
  • LBA45—a randomized multicenter phase II study of pazopanib plus best supportive care (BSC) vs BSC alone in metastatic gastrointestinal stromal tumors (GIST) resistant to imatinib and sunitinib
    Blay, J; Domont, J; Cropet, C
  • ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours
    Chi, P; Chen, Y; Zhang, L
  • A phase Ib/II study of MEK162 (binimetinib [BINI] in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST)
    Chi, P; Qin, L-X; D’Angelo, SP
  • Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors
    Wang, CM; Huang, K; Zhou, Y
  • The activated targets of mTOR signaling pathway are characteristics for PDGFRA mutant and wild-type rather than KIT mutant GISTs
    Sapi, Z; Fule, T; Hajdu, M
  • KIT oncogenic signalint mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway
    Bauer, S; Duensing, A; Demetri, GD; Fletcher, JA
  • Multicenter, single-arm, two-stage phase II trial of everolimus (RAD001) with imatinb in imatinib-resistant patients (pts) with advanced GIST
    Hohenberger, P; Bauer, S; Gruenwald, V
  • A phase I–II study of everolimus (RAD001) in combination with imatinib in patietns with imatinib-resistant gastrointestinal stromal tumors
    Schoffski, P; REichardt, P; Blay, JY
  • GIST treatment options after tyrosine kinase inhibitors
    Songdej, N; Mehren, M
  • A randomized phase II study of perifosine (P) plus imatinib for patients with imatinib-resistnat gastrointestinal stromal tumor (GIST)
    Conley, AP; Araujo, D; Ludwig, J
  • HSP90 and the chaperoning of cancer
    Whitesell, L; Lindquist, SL
  • Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor
    Bauer, S; Yu, LK; Demetri, GD; Fletcher, JA
  • A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft tissue sarcomas
    Wagner, AJ; Chugh, R; Rosen, LS
  • An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST
    Demetri, GD; Heinrich, MC; Chmielowski, B
  • Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors
    Dickson, MA; Okuno, SH; Keohan, ML
  • Activity of AT13387, a novel, non-ansamycin inhibitor of heat shock protein 90, against gastrointestinal stromal tumors (GIST)
    Mahadevan, D; Shapiro, G; Kurtin, SE
  • The immune system and gastrointestinal stromal tumor: a wealth of opportunities
    Tan, Y; Garcia-Buitrago, MT; Trent, JC; Rosenberg, AE
  • Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors
    Dongen, M; Savage, ND; Jordanova, ES
  • PD-1/PD-L1 blockade enhances the efficacy of imatinib in gastrointestinal stromal tumor (GIST)
    Seifert, AM; Kim, TS; Greer, JB
  • Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
    Balachandran, VP; Cavnar, MJ; Zeng, S
  • Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors
    Delahaye, NF; Rusakiewicz, S; Martins, I
  • Combined KIT and CTLA-4 blockade in patients with refractory GIST and other sarcomas
    Shoushtari, AN; D’Angelo, SP; Keohan, ML
  • Exploiting antitumor immunity to overcome relapse and improve remission duration
    Chen, LL; Chen, X; Choi, H
  • Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST
    Gronchi, A; Fiore, M; Miselli, F
  • Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors
    Raut, CP; Posner, M; Desai, J
  • Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor
    DeMatteo, RP; Maki, RG; Singer, S; Gonen, M; Brennan, MF; Antonescu, CR
  • Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib—analysis of prognostic factors (EORTC-STBSG collaborative study)
    Bauer, S; Rutkowski, P; Hohenberger, P
  • Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy
    Hasegawa, J; Kanda, T; Hirota, S
  • Considering the role of radiation therapy for gastrointestinal stromal tumor
    Corbin, KS; Kindler, HL; Liauw, SL
  • External beam radiation therapy for locally advanced and metastatic gastrointestinal stromal tumors
    Cuaron, JJ; Goodman, KA; Lee, N; Wu, AJ
  • Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy: a prospective study
    Joensuu, H; Eriksson, M; Collan, J; Balk, MH; Leyvraz, S; Montemurro, M
  • Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors
    Kobayashi, K; Szklaruk, J; Trent, JC
  • Hepatic artery embolization for liver metastasis of gastrointestinal stromal tumor following imatinib and sunitinib therapy
    Takaki, H; Litchman, T; Covey, A
  • Transcatheter arterial chemoembolization for gastrointestinal stromal tumors with liver metastases
    Cao, G; Li, J; Shen, L; Zhu, X
  • Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors: response, survival and prognostic factors
    Kobayashi, K; Gupta, S; Trent, JC
  • Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma
    Jones, RL; McCall, J; Adam, A
  • A role for adjuvant RFA in managing hepatic metastases from gastrointestinal stromal tumors (GIST) after treatment with targeted systemic therapy using kinase inhibitors
    Hakime, A; Cesne, A; Deschamps, F
  • Radiofrequency ablation for liver metastasis from gastrointestinal stromal tumor
    Yamanaka, T; Takaki, H; Nakatsuka, A
  • Radioembolization in patients with progressive gastrointestinal stromal tumor liver metastases undergoing treatment with tyrosine kinase inhibitors
    Rathmann, N; Diehl, SJ; Dinter, D